CattleTracker Tilts Panels for Cattle

The COP31 Presidency announced a Global Electrification Pledge on November 10 to raise electricity’s share of final energy consumption to 35% by 2035, from around 23% today. Final energy is the energy delivered to users such as households, businesses and factories. The target concerns replacing direct fuel use in transport, buildings and industry with electricity. It is not a target for renewables’ share of electricity generation.

The Presidency also announced an ongoing Electrification Forum, with the International Energy Agency tracking global and regional progress. An IRENA program will help developing countries identify distribution-grid investment needs, prepare projects and access finance. These measures address the infrastructure needed alongside electric vehicles, heating and industrial equipment.

The announcement establishes a goal and supporting initiatives, not an achieved shift in energy use. It does not demonstrate delivered investment, lower bills or emissions cuts; those depend on implementation and how the additional electricity is generated.

COP31 Presidency · Global Electrification Pledge · Source and announcement: November 10, 2026.

First published: November 10, 2026.

Eight governments and ten AI companies signed the Paris Call for AI Safety and Security on November 9, according to the declaration published by France’s presidency. The company signatories include Anthropic, Microsoft, Mistral AI and OpenAI. They support a common approach to evaluating AI risks, shared technical standards and publication of nonsensitive findings.

Developers commit to safeguards that can restrict, pause or shut down model operations within their control, including training and internal use. They also promise to disclose capabilities, limitations and known risks, and support qualified independent evaluation where appropriate and proportionate to the risk. The shutdown commitment does not extend to every third-party copy of an AI model.

The declaration also calls for incident reporting and early warning, while leaving the possible scope of a further cooperation mechanism to be explored. Signing is not evidence that models have become safer or that the safeguards have been demonstrated to work. The text specifies no common implementation deadline or sanctions.

Élysée · Paris Call for AI Safety and Security · Source and announcement: November 9, 2026.

First published: November 10, 2026.

Anthropic announced Claude Fable 5.2 and Claude Mythos 5.2 on November 9. The company describes them as the same underlying model, with Fable adding safeguards for cybersecurity and biology. That is Anthropic’s description of the design, not independent proof that the safeguards prevent misuse.

Fable 5.2 is available across Anthropic’s platforms and through AWS, Google Cloud and Microsoft Azure, according to the announcement. Organizations and professionals seeking direct access to Mythos 5.2 can apply through Anthropic’s Cyber Verification or Life Sciences Verification programs. Applying does not itself guarantee approval.

The distinction is between direct model access and use through a separate product. Claude Enterprise customers can use Claude Security, which includes Mythos 5.2, without joining the Cyber Verification Program. Readers should therefore check which model and access route a product offers, rather than assume both releases are equally open. The announcement alone does not establish a general improvement in reliability, security or scientific results.

Anthropic: Claude Fable 5.2 and Claude Mythos 5.2 · November 9, 2026

Source and launch: November 9, 2026. First published: November 10, 2026.

Updated November 10, 2026. Cure SMA says tumors from three of the nine reported cases have been tested: two were found to be related to Zolgensma treatment, while one appears unrelated. This is the patient organization’s account, not a finding that all nine tumors were caused by treatment. The wider treatment-related risk remains unquantified.

Cure SMA also reports that a November 6 FDA update confirmed an investigation and consideration of further action. According to Cure SMA, the FDA continues to find that the treatment’s benefits outweigh its potential risks and recommends monitoring recipients for tumors. This account is attributed to Cure SMA; the earlier company statement and background below remain part of the record.

Novartis says it has received nine reports of tumors in people previously treated with Zolgensma since the gene therapy’s first approval in 2019. The treatment is used for spinal muscular atrophy, an inherited disease that damages the nerve cells controlling muscles. A November 5 company statement shared by SMA Europe says health authorities were notified in each case.

The statement says two cases showed evidence that DNA delivered by the therapy had integrated into the patients’ DNA. That is not a regulatory finding that Zolgensma caused all nine tumors. Patient organizations say regulators are reviewing the reports; the public statements do not provide a complete case-by-case assessment or establish the size of the treatment-related risk.

The company says more than 6,000 patients have received the therapy across different access programs. Dividing the nine reports by that total would not produce a reliable incidence estimate: the statements do not give comparable follow-up time or show that every case has been captured. These are safety reports under review, not an instruction to change an individual patient’s care.

Novartis statement shared by SMA Europe · November 5, 2026 · Cure SMA community update · November 5, 2026 · EMA medicine overview · SMA background

First published: November 7, 2026.

Updated: November 10, 2026, with Cure SMA’s account of the tested cases and the FDA’s November 6 update.